Risk of tumorigenesis in first-in-human trials of embryonic stem cell neural derivatives: Ethics in the face of long-term uncertainty

Accountability in Research

Volumn 16, Issue 4, 2009, Pages 175-198

  Hess, Pascale G ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Clinical trials; Ethics; Human embryonic stem cells; Neurodegenerative diseases; Spinal cord injury

Indexed keywords

ARTICLE; CLINICAL TRIAL; DEGENERATIVE DISEASE; EMBRYONIC STEM CELL; ETHICS; HUMAN; INFORMED CONSENT; MONITORING; NEOPLASM; RISK ASSESSMENT; SPINAL CORD INJURY; TRANSPLANTATION; UNCERTAINTY;

CLINICAL TRIALS AS TOPIC; EMBRYONIC STEM CELLS; HUMANS; INFORMED CONSENT; MONITORING, PHYSIOLOGIC; NEOPLASMS; NEURODEGENERATIVE DISEASES; RISK ASSESSMENT; SPINAL CORD INJURIES; UNCERTAINTY;

EID: 70449632589     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989620903065145     Document Type: Article

References (55)

1. Advanced Cell Technology. (2009). Retinal pigmented epithelial cell program. Available at: http://www.advancedcell.com/rpe-program. Accessed May 20, 2009.
2. Alper, J. (2009). Geron gets green light for human trial of ES-cell-derived product. Nature Biotechnology 27: 213-214.
3. Amariglio, N., Hirshberg A., Scheithauer, B. W., Cohen, Y., Loewenthal, R., Trakhtenbrot, L., Paz, N., Koren-Michowitz, M., Waldman, D., Leider-Trejo, L., Toren, A., Constantini, S., and Rechavi, G. (2009). Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Medicine 6: 221-230.
4. Andrews, P. W., Matin, M. M., Bahrami, A. R., Damjanov, I., Gokhale, P., and Draper, J. S. (2005). Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: Opposite sides of the same coin. Biochemical Society Transactions, 33: 1526-1530.
5. Baker, M. (2008). Prepping stem cells for the clinic. Nature Reports Stem Cells, April 10 2008. Available at: http://www.nature.com/stemcells/2008/0804/080410/full/stemcells.2008.59.html. Accessed March 30, 2009.
6. Belmont Report. (1979). Protection of human subjects: Ethical principles and guidelines for the protection of human subjects of research. Fed Regist, 44: 23192-23197.
7. Blum, B., and Benvenisty, N. (2008). The tumorigenicity of human embryonic stem cells. Advances in Cancer Research, 100: 133-158.
8. Brederlau, A., Correia, A. S., Anisimov, S. V., Elmi, M., Paul, G., Roybon, L., Morizane, A., Bergquist, F., Riebe, I., Nannmark, U., Carta, M., Hanse, E., Takahashi, J., Sasai, Y., Funa, K., Brundin, P., Eriksson, P. S., and Li, J. Y. (2006). Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells, 24: 1433-1440.
9. Buckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., and Uhm, J. H. (2007). Central nervous system tumors. Mayo Clinic Proceedings, 82: 1271-1286.
10. Cloutier, F., Siegenthaler, M. M., Nistor, G., and Keirstead, H. S. (2006). Transplantation of human embryonic stem cell-derived oligodendrocyte progenitors into rat spinal cord injuries does not cause harm. Regenerative Medicine, 1: 469-479.
11. Council for International Organizations of Medical Sciences (CIOMS). (2002). International ethical guidelines for biomedical research involving human subjects. Available at: www.cioms.ch/frame_guidelines_nov_2002.htm. Accessed March 30, 2009.
12. Couzin, J. (2009). Celebration and concern over U.S. trial of embryonic stem cells. Science, 323:568.
13. Dawson L., Bateman-House, A. S., Mueller Agnew, D., Bok, H., Brock, D. W., Chakravarti, A., Greene, M., King, P. A., O'Brien S. J., Sachs, D. H., Schill, K. E., Siegel, A., Solter, D., Suter, S. M., Verfaillie, C. M., Walters, L. B., Gearhart, J. D., and Faden, R. R. (2003). Safety issues in cell-based intervention trials. Fertility and Sterility, 80: 1077-1085.
14. Deb, K. D., and Sarda, K. (2008). Human embryonic stem cells: preclinical perspectives. Journal of Translational Medicine, 29:7.
15. Emanuel, E. J., Wendler, D., and Grady, C. (2000). What makes clinical research ethical? JAMA, 283: 2701-2011.
16. Edwards, S. (2006). Scrutinizing a stem cell trial. Wired March 29. Available at: http://www.wired.com/medtech/health/news/2006/03/70521. Accessed March 30, 2009.
17. Erdö, F., Bührle, C., Blunk, J., Hoehn, M., Xia, Y., Fleischmann, B., Föcking, M., Küstermann, E., Kolossov, E., Hescheler, J., Hossmann, K. A., and Trapp, T. (2003). Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. Journal of Cerebral Blood Flow and Metabolism, 23: 780-785.
18. Food and Drug Administration (FDA). (2006). Guidance for Industry: Gene therapy clinical trials--Observing subjects for delayed adverse events. Available at: http://www.fda.gov/cber/gdlns/gtclin.pdf. Accessed March 30, 2009.
19. Food and Drug Administration (FDA). (2008a). Briefing Documents: Cellular Therapies Derived from Human Embryonic Stem Cells. Considerations for Pre-Clinical Safety Testing and Patient Monitoring. Available at: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-0471B1_1.pdf. Accessed March 30, 2009.
20. Food and Drug Administration (FDA). (2008b). Transcripts: 45th Meeting of the Center for Biologics Evaluation and Research, Food and Drug Administration. Cellular Therapies Derived from Human Embryonic Stem Cells. Considerations for Pre-Clinical Safety Testing and Patient Monitoring. Available at: http://www.fda.gov/OHRMS/DOCKETS/ac/08/transcripts/2008-0471t1-01.htm (-02, -03, -04, -05). Accessed March 30, 2009.
21. Geron (2009a). Geron receives FDA clearance to begin world's first human clinical trial of embryonic stem cell-based therapy. Available at: http://www.geron.com/grnopc1clearance/ Accessed March 30, 2009.
22. Geron, (2009b). Webcast: Geron receives FDA clearance to begin world's first human clinical trial of embryonic stem cell-based therapy. Available at: http://www.geron.com/grnopc1clearance/ Accessed March 30, 2009.
23. Guillaume, D. J., and Zhang, S. C. (2008). Human embryonic stem cells: a potential source of transplantable neural progenitor cells. Neurosurgical Focus, 24: 1-7.
24. Gruen, L., and Grabel, L. (2006). Concise review: Scientific and ethical roadblocks to human embryonic stem cell therapy. Stem Cells, 24: 2162-2169.
25. Hentze, H., Graichen, R., and Colman, A. (2007). Cell therapy and the safety of embryonic stem cell-derived grafts. Trends in Biotechnology, 25: 24-32.
26. International Society for Stem Cell Research (ISSCR). (2008). Guidelines for the clinical translation of stem cells. Available at: http://www.isscr.org/ clinical_trans/pdfs/ISSCRGLClinicalTrans.pdf. Accessed March 30, 2009.
27. Joannides, A. J., and Chandran, S. (2008). Human embryonic stem cells: An experimental and therapeutic resource for neurological disease. Journal of the Neurological Sciences, 265: 84-88.
28. Keirstead, H. S., Nistor, G., Bernal, G., Totoiu, M., Cloutier, F., Sharp, K., and Steward, O. (2005). Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. Journal of Neuroscience, 25: 4694-4705.
29. Kennedy, P., and Rogers, B. A. (2000). Anxiety and depression after spinal cord injury: A longitudinal analysis. Archives of Physical Medicine and Rehabilitation, 81: 932-937.
30. Kimmelman, J. (2005). Recent developments in gene transfer: Risk and ethics. BMJ.com 330: 79--82.
31. Kimmelman, J., Baylis, F., and Glass, K. C. (2006). Stem cell trials: Lessons from gene transfer research. Hastings Center Report, 36: 23-26.
32. Kimmelman, J. (2008). The ethics of human gene transfer. Nature Reviews Genetics, 9: 239-244.
33. Kishi, Y., Robinson, R. G., and Forrester, A. W. (1995). Comparison between acute and delayed onset major depression after spinal cord injury. Journal of Nervous and Mental Disease, 183: 286-292.
34. Lawrenz, B., Schiller, H., Willbold, E., Ruediger, M., Muhs, A., and Esser, S. (2004). Highly sensitive biosafety model for stem cell-derived grafts. Cytotherapy, 6: 212-222.
35. Levine, R. J. (1988). Ethics and Regulation of Clinical Research (2nd edition). New Haven and London: Yale University Press.
36. Master, Z., McLeod, M., and Mendez, I. (2007). Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson. Journal of Medical Ethics, 33: 169-173.
37. Matzo, M., and Sherman, D. W. (2004). Gerontologic Palliative Care Nursing. St. Louis, MO: Mosby.
38. Mathews, D. J., Sugarman, J., Bok, H., Blass, D. M., Coyle, J. T., Duggan, P., Finkel, J., Greely, H. T., Hillis, A., Hoke, A., Johnson, R., Johnston, M., Kahn J., Kerr D., Kurtzberg J., Liao, S. M., McDonald, J. W., McKhann, G., Nelson, K. B., Rao, M., Regenberg, A., Siegel, A. W., Smith, K., Solter, D., Song, H., Vescovi, A., Young, W., Gearhart, J. D., and Faden, R. (2008). Cell-based interventions for neurologic conditions: Ethical challenges for early human trials. Neurology, 71: 288-293.
39. National Institutes of Health (NIH). (2003). Guidance on Informed Consent for Gene Transfer Research. Available at: http://oba.od.nih.gov/oba/rac/ic/index.html. Accessed March 30, 2009.
40. National Institutes of Health (NIH). (2009a). Assessing human stem cell safety. In Stem Cell Information [World Wide Web site]. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services. Available at: http://stemcells.nih.gov/info/scireport/chapter10. Accessed March 20, 2009.
41. National Institutes of Health (NIH). (2009b). Brain and spinal tumors. Hope through research. Available at: http://www.ninds.nih.gov/disorders/brainandspinaltumors/detail_brainandspinaltumors.html. Accessed March 30, 2009.
42. Park, C. H., Minn, Y. K., Lee, J. Y., Choi, D. H., Chang, M. Y., Shim, J. W., Ko, J. Y., Koh H. C., Kang, M. J., Kang, J. S., Rhie, D. J., Lee, Y. S., Son, H., Moon, S. Y., Kim, K. S., and Lee, S. H. (2005). In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. Journal of Neurochemistry, 92: 1265-1276.
43. Pollack, A. (2009). FDA approves a stem cell trial. New York Times, January 23.
44. Przyborski, S. A. (2005). Differentiation of human embryonic stem cells after transplantation in immune-deficient mice. Stem Cells, 9: 1242-1250.
45. Rao, M. (2008). Scalable human ES culture for therapeutic use: Propagation, differentiation, genetic modification and regulatory issues. Gene Therapy, 15: 82-88.
46. Roy, N., Cleren, C., Singh, S., Yang, L., Beal, M., and Goldman, S. (2006). Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nature Medicine, 12: 1259-1268.
47. Scott, C. T. (2008). Stem cells: New frontiers of ethics, law and policy. Neurosurgery Focus, 24: 1-4.
48. Stojkovic, M., and Daher, S. (2008). Celebrating 10 years of hESC lines: An interview with Peter Andrews. Stem Cells, 27: 4-6.
49. Song, J., Lee, S. T., Kang, W., Park, J. E., Chu, K., Lee, S. E., Hwang, T., Chung, H., and Kim, M. (2007). Human embryonic stem cell-derived neural precursor transplants attenuate apomorphine-induced rotational behavior in rats with unilateral quinolinic acid lesions. Neuroscience Letters, 423: 58-61.
50. Templeton, S. K. (2009). Blind to be cured with stem cells. Sunday Times, April 19.
51. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., and Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282: 1145-1147.
52. Vogel, G. (2005). Ready or not? Human ES cells head toward the clinic. Science, 308: 1534-1538.
53. Yang, D., Zhang, Z. J., Oldenburg, M., Ayala, M., and Zhang, S. C. (2008). Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells, 26: 55-63.
54. Zarin, D. A., and Tse, T. (2008). Moving toward transparency of clinical trials. Science, 319: 1340-1342.
55. Zhang, S. C., Wernig, M., Duncan, I. D., Brüstle, O., and Thomson, J. A. (2001). In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nature Biotechnology, 19: 1129-1133.